Zoetis Inc. (ZTS) CFO Wetteny Joseph Hosts Barclays 27th Annual Global Healthcare (Transcript)
Zoetis Inc. (NYSE:ZTS ) Barclays 27th Annual Global Healthcare March 11, 2025 10:30 AM ET Company Participants Wetteny Joseph - Chief Financial Officer Conference Call Participants Balaji Prasad - Barclays Balaji Prasad Good morning, everyone. Thanks for joining us at the Barclays Healthcare Conference.
Zoetis (ZTS) Laps the Stock Market: Here's Why
Zoetis (ZTS) reachead $170.37 at the closing of the latest trading day, reflecting a +1.87% change compared to its last close.
Zoetis Inc. (ZTS) BofA Securities 2025 Animal Health Summit (Transcript)
Zoetis Inc. (NYSE:ZTS ) BofA Securities 2025 Animal Health Summit February 27, 2025 1:20 PM ET Company Participants Wetteny Joseph - CFO Conference Call Participants Michael Ryskin - Bank of America Operator Ladies and gentlemen, the program is about to begin. At this time, it is my pleasure to turn the program over to your host, Michael Ryskin.
A Once-in-a-Decade Opportunity: 1 Magnificent S&P 500 Dividend Stock Down 36% to Double Up on Right Now
It is a beautiful thing when you find a feel-good stock that offers market-beating potential. A perfect example of this combination today is animal healthcare specialist Zoetis (ZTS 1.93%).
Zoetis CEO on bird flu vaccine
Zoetis received a conditional license for its bird flu vaccine from the US Department of Agriculture to help fight the spread of the disease on poultry farms. Here's what CEO Kristin Peck had to say
Why Zoetis Stock Took Another Tumble Today
One day after unveiling quarterly results that disappointed the market and engendered a stock sell-off, Zoetis (ZTS -4.49%) shares again tumbled. As of late-session trading on Friday, they were down by 4%, in no small part due to several analyst price target cuts.
US grants conditional clearance to Zoetis' bird flu vaccine for poultry
Zoetis said on Friday its bird flu vaccine has received the U.S. Department of Agriculture's conditional license for use in poultry.
Zoetis CEO says Avian Flu vaccine for poultry gets USDA approval
Zoetis CEO Kristin Peck joins 'Closing Bell Overtime' to talk its Avian Flu vaccine, the impact of tariffs, and more.
Zoetis: In-Line Q4 Earnings And Weak Guidance Present A Buying Opportunity
Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance, presenting a buying opportunity around $163/share. Zoetis' unique advantages and pricing power in animal health, coupled with high R&D investment and a wide moat, make it a strong long-term play on emerging market growth. Despite regulatory risks and currency headwinds, Zoetis' dependable earnings and high operating margins justify a 12-month price target of $200/share.
Zoetis Stock Down Despite Q4 Earnings & Revenues Beat Estimates
ZTS stock falls despite better-than-expected fourth-quarter results due to a weak 2025 outlook.
Zoetis Inc. (ZTS) Q4 2024 Earnings Call Transcript
Zoetis Inc. (NYSE:ZTS ) Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ET Company Participants Steve Frank - IR Kristin Peck - CEO Wetteny Joseph - CFO Conference Call Participants Michael Ryskin - Bank of America Erin Wright - Morgan Stanley Jon Block - Stifel Russell Yuen - William Blair Balaji Prasad - Barclays Chris Schott - JPMorgan Glen Santangelo - Jefferies Navann Ty - BNP Paribas Chris LoBianco - TD Securities Andrea Alfonso - UBS Daniel Clark - Leerink Partners Operator Welcome to the Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis.
Why Zoetis Stock Was Falling Today
Shares of Zoetis (ZTS -6.17%), the leading animal pharmaceutical company, were sliding today after its 2025 guidance came up short in its fourth quarter.
